What if AF could be controlled without destroying the atrium?
MaxWell Biomedical is pioneering Cardiomodulation™, a new class of non-destructive electrical therapy designed to restore organized rhythm while preserving atrial function in people living with atrial fibrillation.
THE UNMET NEED
AF begins as an electrical disorder. Its impact is mechanical.
AF begins as an electrical disorder, but over time it can become a progressive disease of atrial structure and function. As the atrium remodels, coordinated contraction declines, reducing the “atrial kick” that supports ventricular filling and cardiac output.
Current therapies focus primarily on controlling the rhythm. Medications manage heart rate or rhythm but do not directly restore atrial mechanics. Ablation can reduce AF burden, but it works by creating scar and is not specifically designed to restore coordinated atrial function.
Sinus rhythm on an ECG does not always mean the atrium has recovered its mechanical function.
1 in 7
strokes is caused by atrial fibrillation.
Source: CDC
~5x
higher risk of ischemic stroke linked to AF, independent of other risk factors.
Source: CDC
AF is an electrical disorder. Why must treating it require destroying tissue?
A NEW CATEGORY
Four ways to approach AF. Only one is designed to restore sinus rhythm and resynchronize atrial activation without destroying tissue.
DRUGS
Manage rate or rhythm systemically, throughout the whole body. They do not address atrial mechanics.
CARDIOVERSION
A synchronized electrical shock, usually given under sedation, resets the heart to normal rhythm. AF often returns. This doesn't address the atrial remodeling that drives the disease.
ABLATION
Creates scar tissue to block abnormal electrical signals. Reduces arrhythmia burden but is not designed to restore atrial pump function.
CARDIOMODULATION™
Being developed to use precisely timed, targeted electrical therapy to organize rhythm, resynchronize the atrial activation and preserve the tissue needed for mechanical function.
Medicine Evolves
1980s
Surgical incisions create lines of scar.
1990s → present day
Energy delivered by catheter creates scar.
Future
Non-destructive therapy designed to restore sinus rhythm and atrial function.
We don’t want to destroy the chaos. We want to organize it.
THE RHYTHM360™ PLATFORM
Modulate.
Resynchronize.
Restore.
Rhythm360 is being developed as a closed-loop Cardiomodulation™ platform. It is designed to continuously monitor atrial rhythm and deliver precisely timed, spatially targeted electrical therapy only when needed.
MOMENTUM
Progress you can verify.
Financing Completed
We are excited to announce that MaxWell Biomedical has closed a new financing round! This funding strengthens our path toward delivering a non-destructive, atrial-focused resynchronization therapy designed to restore coordinated atrial mechanics and functional sinus rhythm in patients with atrial fibrillation and heart failure.
Thank you to the investors who share our conviction, the clinicians pushing the science forward, and the team building what doesn’t yet exist.
Onward!
5 Abstracts Accepted
Three abstracts were accepted at the Heart Rhythm Society (HRS) 2026 Annual Scientific Sessions:
Closed-loop Adaptive Pacing Outperforms Programmed Sequences for AF Termination
Termination of Atrial Fibrillation via Spatial Resynchronization Therapy (SRT)
Left Atrial Multisite Pacing (LAMSP) Achieves Global Control, Cycle Length Prolongation and AF Termination in Atrial Fibrillation: First-in-Human Results
Two abstracts were accepted at the European Heart Rhythm Association (EHRA) 2026 Congress:
Left atrial multi-site pacing achieves up to 10x greater AF cycle length prolongation vs. catheter ablation
Real-Time Global Control Index for Adaptive Atrial Resynchronization: A Quantitative Mechanism for Novel AF Therapy.